Skip to main content
OpenTrials
Completed

NCT Number: NCT02985567

An Observational Study of the Use of Chloral Hydrate for Ophthalmic Procedures in Children

The study involves a prospective evaluation of chloral hydrate sedation for the measurement of intraocular pressure in children ages one month to five years of age.

Completed

Looking for future studies?

Notify Me

Key information

Age range

1 month–5 year

Sex eligibility

All sexes

Study type

Observational

Primary location

King Khaled Eye Specialist Hospital (KKESH)

Riyadh, Riyadh Region, 12329, Saudi Arabia

About this study

This study will be a prospective, non-randomized trial of children 1 month to 5 years of age who are determined to require a sedation procedure at the King Khaled Eye Specialist Hospital (KKESH). There will be two parts to the consent process. Oral consent will be administered to subjects who are not undergoing eye pressure evaluation. These children have chloral hydrate sedation for imaging or other eye evaluations. For these children, we will prospectively monitor the success rate of chloral hydrate sedation such that a complete ophthalmic or imaging evaluation could be performed and will determine the proportion of adverse events that occur due to sedation including vomiting, respiratory distress or depression, alterations in vital signs beyond reference ranges for normal sleeping children, hypoxia with oxygen saturation <90%, and unplanned hospital admission. No testing will be performed for study purposes on these individuals.

For children undergoing sedation who will have intraocular pressure measurements for clinical care purposes, we will perform additional eye pressure measurements as part of the research protocol. Written consent will be obtained to allow us to additionally measure their intraocular pressure as specified below.

After recruitment and completion of informed consent procedures by parents, subjects' medical and ocular history will be reviewed by a study ophthalmologist and one of two pediatricians overseeing sedation procedures. Patients unable to undergo intraocular pressure measurement due to infection or ocular surface disease and those in whom chloral hydrate sedation is medically contraindicated will be excluded. Age, gender, diagnosis, current medications and surgical history will be recorded from the clinical chart for all subjects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ages 1 month to five years
  • require sedation for ophthalmic care

Exclusion criteria

  • weight <3 kg or >20 kg
  • infection/ocular surface disease
  • medical contraindication of chloral hydrate
  • green or gray nasal discharge
  • fever, productive cough, chest retractions, or other signs of respiratory infection
  • oxygen saturation < 90%
  • active infectious disease such as rubella or varicella
  • rectal or tympanic temperature > 37.7 degrees, or oral or temporal artery temperature > 37.2 degrees
  • history of current ongoing vomiting and diarrhea
  • anemia (Hgb < 9.0mg),
  • history of seizure in past 6 weeks

Treatment and study plan

Intraocular pressure evaluation

Other

Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.

Primary outcomes

  1. Change in intraocular pressure during chloral hydrate sedation

    Time frame: 25 minutes after sedation to 125 minutes after sedation

    Unit- mmHg

Secondary outcomes

  1. Chloral hydrate dose required for successful sedation

    Time frame: Adminstration to adequate sedation (up to 30 minutes)

    Unit- mg

  2. Time to recovery

    Time frame: Sedation induction to 125 minutes after sedation

    Unit- minutes

  3. Hear rate under sedation

    Time frame: Sedation induction to 125 minutes after sedation

    Unit- beats per minute

  4. Blood pressure under sedation

    Time frame: Sedation induction to 125 minutes after sedation

    Unit- mmHg

  5. Oxygen saturation under sedation

    Time frame: Sedation induction to 125 minutes after sedation

    Unit- %

  6. Adverse events related to chloral hydrate sedation

    Time frame: Sedation induction to 125 minutes after sedation

    Unit- number of events (that occur from the following list) Vomiting, subclinical respiratory depression, recovery agitation, oxygen desaturation, airway obstruction, failed sedation, bradycardia, tachycardia, hypotension, hypertension, seizure, aspiration, apnea, arrhythmia, cardiac arrest Unit- number of events (that occur from the following list) Vomiting, subclinical respiratory depression, recovery agitation, oxygen desaturation, airway obstruction, failed sedation, bradycardia, tachycardia, hypotension, hypertension, seizure, aspiration, apnea, arrhythmia, cardiac arrest Unit- number of events (that occur from the following list) Vomiting, subclinical respiratory depression, recovery agitation, oxygen desaturation, airway obstruction, failed sedation, bradycardia, tachycardia, hypotension, hypertension, seizure, aspiration, apnea, arrhythmia, cardiac arrest

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Collaborators

  • King Khaled Eye Specialist Hospital

Registry information

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Dec 7, 2016
Registry last updated
Dec 7, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.